Japanese Prefectures Struggle To Meet New Goals Of Flu Drug Stockpiles
This article was originally published in PharmAsia News
Nearly a third of Japan's 47 prefectures have increased their stock of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) to treat H1N1 flu cases should they occur. The 15 are stepping up their stockpiling of the drugs to meet a national government target of being able to treat as much as 45 percent of the population. A survey shows the stockpiling success varies widely by prefecture, with some nearly complete and others still struggling. The Japanese system calls for the central government to obtain half the drugs and each prefecture to acquire the other half. (Click here for more
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.